ABBV-3373-A NOVEL IMMUNOLOGY ANTIBODY DRUG CONJUGATE: RESULTS FROM A FIRST-IN-HUMAN SINGLE ASCENDING DOSE STUDY IN HEALTHY SUBJECTS TO SUPPORT DOSE SELECTION FOR THE PROOF-OF-CONCEPT STUDY IN RHEUMATOID ARTHRITIS PATIENTS.

被引：0
|
作者：
D'Cunha, R. [1 ]
Kupper, H. [2 ]
Arikan, D. [1 ]
Zhao, W. [1 ]
Ruzek, M. [3 ]
Kang, B. [3 ]
Doelger, E. [2 ]
Carter, D. [1 ]
Pang, Y. [1 ]
机构：
[1] AbbVie, N Chicago, IL 60064 USA
[2] AbbVie Deutschland, Ludwigshafen, Germany
[3] AbbVie Biores Ctr, Worcester, MA USA
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2021年 / 109卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
PIV-058
引用
收藏
页码：S78 / S79
页数：2
相关论文
共 25 条
  • [21] YL201, a novel B7H3-targeting antibody-drug conjugate (ADC), in patients (pts) with advanced solid tumors: Results from a first-in-human phase I study
    Zhao, H.
    Ma, Y.
    Meng, X.
    Wu, L.
    Fan, Y.
    Zheng, Y.
    Liu, Z.
    Ji, Y.
    Lv, D.
    Luo, S.
    Sommerhalder, D.
    Fu, S.
    Huang, Y.
    Yang, Y.
    Fang, W.
    Zhao, Y.
    Wang, Y.
    Chin, S.
    Xue, T.
    Zhang, L.
    ANNALS OF ONCOLOGY, 2024, 35 : S485 - S485
  • [22] A phase lb, first-in-human, dose escalation and expansion study of XMT-1522, a novel antibody-drug conjugate (ADC) directed against HER2, in patients with advanced breast cancer and other advanced tumors expressing HER2.
    Burris, Howard A.
    Barve, Minal A.
    Hamilton, Erika Paige
    Bardia, Aditya
    Soliman, Hatem Hussein
    Jarlenski, Donna
    Mosher, Rebecca
    Bergstrom, Donald Alan
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [23] Dose escalation results from a first-in-human, phase I/II study of GB263T, a novel EGFR/cMET/cMET trispecific antibody, in patients with advanced EGFR-mutated (EGFRm) non-small cell lung cancer (NSCLC)
    Yang, Jin-Ji
    Pavlakis, Nick
    Xie, Fan
    Li, Tong
    Wu, Yi-Long
    MOLECULAR CANCER THERAPEUTICS, 2023, 22 (12)
  • [24] SIRUKUMAB, A HUMAN ANTI-IL-6 MONOCLONAL ANTIBODY, IMPROVES PHYSICAL FUNCTION IN PATIENTS WITH ACTIVE RA DESPITE METHOTREXATE THERAPY: RESULTS FROM A 2-PART, PROOF-OF-CONCEPT, DOSE-RANGING, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 STUDY
    Hsu, B.
    Chiou, C. -F.
    Sheng, S.
    Smolen, J.
    Weinblatt, M.
    ANNALS OF THE RHEUMATIC DISEASES, 2013, 71 : 373 - 373
  • [25] Preliminary dose escalation results from a first-in-human, phase I/II study of GB263T, a novel EGFR/cMET/cMET trispecific antibody, in patients with advanced EGFR-mutated (EGFRm) non-small cell lung cancer (NSCLC)
    Yang, Jin-Ji
    Pavlakis, Nick
    Xie, Fan
    Wu, Yi-Long
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
123